PDF(Pubmed)
Abstract：
UNASSIGNED: Doxorubicin (DOX) is used to treat various types of cancers. However, its use is restricted by cardiotoxicity, a leading cause of morbidity and mortality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may be associated with cardioprotective properties.
UNASSIGNED: This study aims to determine the protective effects of different semaglutide (SEM) doses on DOX-induced cardiotoxicity in a rat model.
UNASSIGNED: Thirty-five female Wistar rats were divided into five groups. The first group received distilled water as a negative control (NC); the positive control (PC) group received distilled water plus DOX; the third group (SL) received a low dose of SEM (0.06 mg/kg) plus DOX; the fourth group (SM) received a moderate dose of SEM (0.12 mg/kg) plus DOX; and the fifth group (SH) received a high dose of SEM (0.24 mg/kg) plus DOX. Blood samples were collected on day 8 to assess serum troponin, lactate dehydrogenase (LDH), creatine phosphokinase (CPK), total lipid profile, and vascular cell adhesion molecule 1 (VCAM-1). Cardiac tissue was sent for histopathological analysis.
UNASSIGNED: DOX increased the total cholesterol (TC), low-density lipoprotein (LDL), triglyceride (TG), LDH, and CKP levels. Moderate and high doses of semaglutide significantly reduced serum cholesterol levels (*p = 0.0199), (**p = 0.0077), respectively. A significant reduction (***p = 0.0013) in total body weight after treatment with SEM was observed in the SL group and a highly significant reduction (****p < 0.0001) was observed in the SM and SH groups. SEM at all doses reduced CPK levels. The SL group showed a significant reduction in troponin level (*p=0.0344). Serum LDH levels were reduced by all three SEM doses. The histopathological findings support the biochemical results.
UNASSIGNED: Semaglutide may possess cardioprotective properties against DOX-induced cardiotoxicity in a rat model by decreasing serum biochemical markers of cardiotoxicity.
UNASSIGNED: This study aims to determine the protective effects of different semaglutide (SEM) doses on DOX-induced cardiotoxicity in a rat model.
UNASSIGNED: Thirty-five female Wistar rats were divided into five groups. The first group received distilled water as a negative control (NC); the positive control (PC) group received distilled water plus DOX; the third group (SL) received a low dose of SEM (0.06 mg/kg) plus DOX; the fourth group (SM) received a moderate dose of SEM (0.12 mg/kg) plus DOX; and the fifth group (SH) received a high dose of SEM (0.24 mg/kg) plus DOX. Blood samples were collected on day 8 to assess serum troponin, lactate dehydrogenase (LDH), creatine phosphokinase (CPK), total lipid profile, and vascular cell adhesion molecule 1 (VCAM-1). Cardiac tissue was sent for histopathological analysis.
UNASSIGNED: DOX increased the total cholesterol (TC), low-density lipoprotein (LDL), triglyceride (TG), LDH, and CKP levels. Moderate and high doses of semaglutide significantly reduced serum cholesterol levels (*p = 0.0199), (**p = 0.0077), respectively. A significant reduction (***p = 0.0013) in total body weight after treatment with SEM was observed in the SL group and a highly significant reduction (****p < 0.0001) was observed in the SM and SH groups. SEM at all doses reduced CPK levels. The SL group showed a significant reduction in troponin level (*p=0.0344). Serum LDH levels were reduced by all three SEM doses. The histopathological findings support the biochemical results.
UNASSIGNED: Semaglutide may possess cardioprotective properties against DOX-induced cardiotoxicity in a rat model by decreasing serum biochemical markers of cardiotoxicity.
摘要：
■阿霉素（DOX）用于治疗各种类型的癌症。然而,它的使用受到心脏毒性的限制，发病率和死亡率的主要原因。胰高血糖素样肽1受体激动剂（GLP-1RA）可能与心脏保护特性有关。
■本研究旨在确定不同司马鲁肽（SEM）剂量对大鼠模型中DOX诱导的心脏毒性的保护作用。
■将35只雌性Wistar大鼠分为5组。第一组接受蒸馏水作为阴性对照（NC）；阳性对照（PC）组接受蒸馏水加DOX；第三组（SL）接受低剂量SEM（0.06mg/kg）加DOX；第四组（SM）接受中等剂量SEM（0.12mg/kg）加DOX；第五组（SH）接受高剂量SEM（0.24mg/kg）加DOX。在第8天收集血样以评估血清肌钙蛋白，乳酸脱氢酶（LDH），肌酸磷酸激酶（CPK），总脂谱，和血管细胞粘附分子1（VCAM-1）。送心脏组织进行组织病理学分析。
■DOX增加了总胆固醇（TC），低密度脂蛋白（LDL），甘油三酯（TG），LDH,和CKP水平。中、高剂量司马鲁肽显著降低血清胆固醇水平（*p=0.0199），（**p=0.0077），分别。在用SEM处理后,在SL组中观察到总体重的显著降低(***p=0.0013),并且在SM和SH组中观察到高度显著降低(***p<0.0001)。在所有剂量下的SEM降低CPK水平。SL组显示肌钙蛋白水平显著降低(*p=0.0344)。所有三个SEM剂量均降低了血清LDH水平。组织病理学发现支持生化结果。
■通过降低心脏毒性的血清生化标志物，在大鼠模型中，塞马鲁肽可能具有针对DOX诱导的心脏毒性的心脏保护特性。
■本研究旨在确定不同司马鲁肽（SEM）剂量对大鼠模型中DOX诱导的心脏毒性的保护作用。
■将35只雌性Wistar大鼠分为5组。第一组接受蒸馏水作为阴性对照（NC）；阳性对照（PC）组接受蒸馏水加DOX；第三组（SL）接受低剂量SEM（0.06mg/kg）加DOX；第四组（SM）接受中等剂量SEM（0.12mg/kg）加DOX；第五组（SH）接受高剂量SEM（0.24mg/kg）加DOX。在第8天收集血样以评估血清肌钙蛋白，乳酸脱氢酶（LDH），肌酸磷酸激酶（CPK），总脂谱，和血管细胞粘附分子1（VCAM-1）。送心脏组织进行组织病理学分析。
■DOX增加了总胆固醇（TC），低密度脂蛋白（LDL），甘油三酯（TG），LDH,和CKP水平。中、高剂量司马鲁肽显著降低血清胆固醇水平（*p=0.0199），（**p=0.0077），分别。在用SEM处理后,在SL组中观察到总体重的显著降低(***p=0.0013),并且在SM和SH组中观察到高度显著降低(***p<0.0001)。在所有剂量下的SEM降低CPK水平。SL组显示肌钙蛋白水平显著降低(*p=0.0344)。所有三个SEM剂量均降低了血清LDH水平。组织病理学发现支持生化结果。
■通过降低心脏毒性的血清生化标志物，在大鼠模型中，塞马鲁肽可能具有针对DOX诱导的心脏毒性的心脏保护特性。
